The Allergan Foundation And The Jed Foundation Announce Three-Year $300,000 Scholarship Fund To Support JED Campus Program

The JED Campus Program helps participating colleges and universities assess and improve their mental health, substance abuse, and suicide prevention policies and programming. Beyond supporting schools in these critical, under-resourced areas, this initiative also brings the importance of  mental health to the forefront of national attention.

"The Allergan Foundation is proud to support the critical work of The Jed Foundation in advancing initiatives that help support the mental health and well-being of America's college students," said Gwyn Grenrock, Executive Director, The Allergan Foundation. "Through this commitment to the JED Campus Program, we will have a direct impact on helping to create a positive atmosphere for addressing mental health issues and fostering well-being across many of America's college campuses for hundreds of thousands of students who need support during a very dynamic, challenging time in their lives."

"We are grateful to The Allergan Foundation for its generous support to enhance critical mental health programming and emotional health resources for more than 500,000 students nationwide," said John MacPhee, Executive Director and CEO, The Jed Foundation. "The new scholarship fund will enable more than 50 additional universities to participate in the JED Campus Program, and we are hopeful that, as the scholarship fund grows, we will be able to continue expanding access and capabilities to help build safer, healthier campus communities across the country."

About the JED Campus Program

By becoming a member of the JED Campus Program, a school demonstrates a commitment to the emotional well-being of its students. Participating schools embark on a multi-year strategic partnership with The Jed Foundation to assess and enhance the work that is already being done, and also help to create positive, lasting systemic change in the campus community.

Over the course of their participation in the program, JED Campus schools receive:

• Support in the development of an interdisciplinary, campus-wide team that includes senior leadership to steer this work at their university
• An in-depth, confidential self-assessment survey at the beginning of the program and then again after three years, assessing mental health promotion and substance abuse and suicide prevention efforts
• Customized feedback reports created by JED's clinical team after each survey identifying successes and opportunities for enhancement
• An onsite meeting with a JED expert to develop a strategic plan tailored to a school's individual needs that will serve as a roadmap to implement enhancements over the course of the program
• Ongoing support from a dedicated JED Campus Manager who provides consultation, guidance and resources to help each school achieve its goals
• Membership in a nationwide Learning Community – a network of JED Campus Program schools that share advice and experiences as well as presentations/discussions on specific topics of interest that emerge from JED's work with the schools
• The JED Campus Program membership seal to signify the school's commitment to student mental health

About the Allergan Foundation

The Allergan Foundation is a U.S.-based, private charitable foundation committed to providing a lasting and positive impact in the communities in which Allergan plc employees live and work. In addition to allocating resources primarily on health and human services, the Foundation conducts grant making in support of civic and community programs, education and the arts. Since its inception in 1998, The Allergan Foundation has distributed over $60 million to a wide variety of philanthropic pursuits – improving lives, elevating communities.

About The Jed Foundation

The Jed Foundation (JED) is a national nonprofit that exists to protect the emotional health of our country's 40 million high school and college students and reduce their risks of substance abuse and suicide. We're partnering with high schools and colleges to help strengthen their mental health, substance abuse and suicide prevention programming and systems. We're developing accessible resources and powerful partnerships so that students have the support they need, when and how they need it, and we're encouraging awareness, understanding and action around mental health issues.

Learn more at www.jedfoundation.org. Check out our programs including: JED Campus Program (www.thecampusprogram.org), ULifeline (www.ulifeline.org), Half of Us (www.halfofus.com), Love is Louder (www.loveislouder.com), and Transition Year (www.transitionyear.org). 

Follow JED on social media: Twitter | Facebook | Instagram | YouTube | LinkedIn

About Allergan

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma.  Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

CONTACTS:

ALLERGAN 
Mark Marmur 
(862) 261-7558

JED FOUNDATION 
Jon Colucci 
Makovsky for The Jed Foundation 
(212) 508-9646

Logo - http://photos.prnewswire.com/prnh/20160607/376578LOGO
Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

SOURCE The Allergan Foundation